Breast Cancer

Breast cancer, a malignant tumor originating in the epithelial cells of the breast, is one of the most common cancers among women and one of the leading causes of cancer deaths in women. The incidence of breast cancer is related to a number of factors, including heredity, age, hormone levels, and lifestyle. Based on the characteristics of tumor cells, breast cancer can be classified into different subtypes, such as hormone receptor positive (ER+/PR+), human epidermal growth factor receptor 2 (HER2+), and triple-negative breast cancer (TNBC).

In recent years, significant progress has been made in breast cancer treatment and drug development. Especially in the field of targeted therapy and immunotherapy, the continuous emergence of new drugs and therapies has brought more treatment options and better prognosis for patients.

Targeted therapy drugs:

● HER2 positive breast cancer

The treatment of HER2-positive breast cancer has made significant progress in the past few years.ADC (Antibody Drug Coupling Compound)-based drug therapy is an important breakthrough in the treatment of HER2-positive breast cancer. For example, DS-8201 (Trastuzumab Deruxtecan), an ADC drug targeting HER2, has shown potential efficacy in clinical trials in patients with low HER2 expression and HER2-negative breast cancer.67 Additionally, T-DM1 (Trastuzumab Emtansine) and T-DXd ( Trastuzumab Deruxtecan) have also been successful in the treatment of HER2-positive breast cancer.

● Hormone receptor positive breast cancer

For hormone receptor-positive breast cancer, the development of CDK4/6 inhibitors such as abemaciclib, dalciclib, and ribociclib has provided new treatment options for patients. These drugs slow the growth and spread of tumor cells by inhibiting key regulators of the cell cycle.

● Triple Negative Breast Cancer

Triple-negative breast cancer (TNBC) is one of the more difficult subtypes to treat because it lacks hormone receptors and HER2 expression. However, immunotherapy has made progress in this area, for example PD-1/PD-L1 inhibitors have shown potential in the treatment of TNBC.

Immunotherapy drugs:

Immunotherapy is another important advance in the field of breast cancer treatment. Immune checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, have shown some efficacy in the treatment of triple negative breast cancer. In addition, researchers are exploring strategies to use immunotherapy in conjunction with other therapies to improve treatment outcomes.

Breast Cancer Drug Target Related Products

● Target Proteins

ERBB2
CSB-MP007763HU

Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC₅₀ is 2.179-2.825 ng/ml.

PDCD1
CSB-MP619964HU1

Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC₅₀ of human PD-1 protein is 6.087-7.854 ng/ml.

CD274
CSB-MP878942HU1

Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody (CSB-MA878942A1m, antigen from E.coli), the EC₅₀ of human PD-L1 protein is 1.252-1.653 ng/mL

TACSTD2
CSB-MP023072HU1

Measured in cell activity assay using U937 cells, the EC₅₀ for this effect is 190.2-298.6 ng/ml.

ERBB3
CSB-MP007765HU

Measured by its binding ability in a functional ELISA. Immobilized NRG1 (CSB-MP016077HU1(F6)) at 2 μg/ml can bind human ERBB3, the EC₅₀ is 12.32-15.74 ng/ml.

CTLA4
CSB-MP006163HU1

Measured by its binding ability in a functional ELISA. Immobilized CD152 at 2 μg/ml can bind Anti-CD152 rabbit monoclonal antibody (CSB-RA213310A0HU), the EC₅₀ of human CD152 protein is 27.14-34.82 ng/ml.

CD47
CSB-MP004940HU

Human SIRPA protein His/Myc tag (CSB-MP021334HU) captured on COOH chip can bind Human CD47 protein Fc tag (CSB-MP004940HU) with an affinity constant of 19.1 nM as detected by LSPR Assay.

EGFR
CSB-MP007479HU

Human EGF protein captured on COOH chip can bind Human EGFR protein, his and Myc tag (CSB-MP007479HU) with an affinity constant of 11.9nM as detected by LSPR Assay.

Product Name	Code	Target	Source	Tag Info
Recombinant Human Programmed cell death 1 ligand 1 (CD274), partial (Active)	CSB-MP878942HU1	CD274	Mammalian cell	C-terminal hFc-tagged
Recombinant Human CD276 antigen (CD276), partial (Active)	CSB-MP733578HU	CD276	Mammalian cell	C-terminal hFc-Myc-tagged
Recombinant Human Tumor necrosis factor receptor superfamily member 5 (CD40), partial (Active)	CSB-MP004936HU1	CD40	Mammalian cell	C-terminal hFc-tagged
Recombinant Macaca fascicularis CD44 antigen (CD44), partial (Active)	CSB-MP4290MOV	CD44	Mammalian cell	C-terminal 10xHis-tagged
Recombinant Human CD44 antigen (CD44), partial, Biotinylated (Active)	CSB-MP004938HU(F1)j1-B	CD44	Mammalian cell	C-terminal mFc-Avi-tagged
Recombinant Human CD44 antigen (CD44), partial (Active)	CSB-MP004938HU(F1)	CD44	Mammalian cell	C-terminal hFc-tagged
Recombinant Human Leukocyte surface antigen CD47 (CD47), partial (Active)	CSB-MP004940HU	CD47	Mammalian cell	C-terminal hFc-tagged
Recombinant Human Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) (E398K) (Active)	CSB-MP005165HU	CEACAM5	Mammalian cell	C-terminal 10xHis-tagged
Recombinant Human Cytotoxic T-lymphocyte protein 4 (CTLA4), partial (Active)	CSB-MP006163HU1	CTLA4	Mammalian cell	C-terminal hFc-tagged
Recombinant Human Epidermal growth factor receptor (EGFR), partial (Active)	CSB-MP007479HU	EGFR	Mammalian cell	N-terminal 10xHis-tagged and C-terminal Myc-tagged
Recombinant Human Receptor tyrosine-protein kinase erbB-2 (ERBB2), partial (Active)	CSB-MP007763HU	ERBB2	Mammalian cell	C-terminal 6xHis-tagged
Recombinant Human Receptor tyrosine-protein kinase erbB-3 (ERBB3), partial (Active)	CSB-MP007765HU	ERBB3	Mammalian cell	C-terminal hFc-tagged
Recombinant Human Interleukin-2 (IL2) (Active)	CSB-MP011629HU	IL2	Mammalian cell	N-terminal hFc-tagged
Recombinant Human Interleukin-2 receptor subunit alpha (IL2RA), partial (Active)	CSB-MP011649HU3	IL2RA	Mammalian cell	C-terminal 10xHis-tagged
Recombinant Human Hepatocyte growth factor receptor (MET), partial (Active)	CSB-MP013714HU	MET	Mammalian cell	C-terminal hFc-tagged
Recombinant Human Mesothelin (MSLN), partial (Active)	CSB-MP015044HUc9	MSLN	Mammalian cell	N-terminal hFc-tagged
Recombinant Human Mucin-16 (MUC16), partial (Active)	CSB-MP704410HU3c7	MUC16	Mammalian cell	C-terminal 6xHis-tagged
Recombinant Human Nectin-4 (NECTIN4), partial (Active)	CSB-MP822274HU	NECTIN4	Mammalian cell	C-terminal 10xHis-tagged
Recombinant Human 5'-nucleotidase (NT5E) (Active)	CSB-MP723415HU	NT5E	Mammalian cell	C-terminal 6xHis-tagged
Recombinant Human Programmed cell death protein 1 (PDCD1), partial (Active)	CSB-MP619964HU1	PDCD1	Mammalian cell	C-terminal 6xHis-tagged

• 1
• 2

● Cell Lines

CT26/Human ROR1 Stable Cell Line

CSB-SC020067HU

Untransfected CT26 cells (green line) and transfected Human ROR1 CT26 stable cells (red line) were stained with anti-ROR1 antibody (CSB-RA020067A1HU) (2µg/1*10⁶ cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.

● Recombinant antibodies

ERBB2 Recombinant Monoclonal Antibody
CSB-RA260392A0HU

IHC image of CSB-RA260392A0HU diluted at 1:100 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system.

MET Recombinant Monoclonal Antibody
CSB-RA634199A0HU

IHC image of CSB-RA634199A0HU diluted at 1:100 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system.

CD44 Recombinant Monoclonal Antibody
CSB-RA292372A0HU

Overlay Peak curve showing Hela cells surface stained with CSB-RA292372A0HU (red line) at 1:50.

EGFR Recombinant Monoclonal Antibody
CSB-RA159341A0HU

Overlay histogram showing Jurkat cells stained with CSB-RA159341A0HU (red line) at 1:50.

Product Name	Code	Target	Species Reactivity	Tested Applications
CA9 Recombinant Monoclonal Antibody	CSB-RA614990A0HU	CA9	Human	ELISA, IHC
CD247 Recombinant Monoclonal Antibody	CSB-RA244537A0HU	CD247	Human	ELISA, FC
CD27 Recombinant Monoclonal Antibody	CSB-RA953976A0HU	CD27	Human	ELISA, WB
CD274 Recombinant Monoclonal Antibody	CSB-RA977797A0HU	CD274	Human	ELISA, WB, IHC
CD274 Recombinant Monoclonal Antibody	CSB-RA878942MA1HU	CD274	Human	ELISA, IHC, FC
CD40 Recombinant Monoclonal Antibody	CSB-RA004936MA1HU	CD40	Human	ELISA, IF, FC
CD44 Recombinant Monoclonal Antibody	CSB-RA004938A0HU	CD44	Human	ELISA, WB, IHC
CD44 Recombinant Monoclonal Antibody	CSB-RA292372A0HU	CD44	Human	ELISA, WB, IHC, IF, FC
CD44 Recombinant Monoclonal Antibody	CSB-RA004938MA1HU	CD44	Human	ELISA, FC
CD47 Recombinant Monoclonal Antibody	CSB-RA802124A0HU	CD47	Human	ELISA, WB, IHC, IF
CEACAM5 Recombinant Monoclonal Antibody	CSB-RA005165MA3HU	CEACAM5	Human	ELISA, IF, FC
CEACAM5 Recombinant Monoclonal Antibody	CSB-RA005165MA1HU	CEACAM5	Human	ELISA
CTLA4 Recombinant Monoclonal Antibody	CSB-RA213310A0HU	CTLA4	Human	ELISA, IHC
CTLA4 Recombinant Monoclonal Antibody	CSB-RA006163MA1HU	CTLA4	Human, Mouse	ELISA, WB, IF, FC
Phospho-EGFR (Y1092) Recombinant Monoclonal Antibody	CSB-RA007479A1092phHU	EGFR	Human	ELISA, WB
Phospho-EGFR (Y1068) Recombinant Monoclonal Antibody	CSB-RA007479A1068phHU	EGFR	Human	ELISA, WB
EGFR Recombinant Monoclonal Antibody	CSB-RA159341A0HU	EGFR	Human	ELISA, WB, IHC, IF, FC
EGFR Recombinant Monoclonal Antibody	CSB-RA794061A0HU	EGFR	Human	ELISA, WB, IHC
EGFR Recombinant Monoclonal Antibody	CSB-RA159341MA1HU	EGFR	Human	ELISA, IHC, FC
EPCAM Recombinant Monoclonal Antibody	CSB-RA932207A0HU	EPCAM	Human	ELISA, WB

• 1
• 2
• 3

● ELISA Kits

Product Name	Code	Target	Detection Range	Sensitivity
Human Carbonic Anhydrase 9(CA9) ELISA Kit	CSB-E13266h	CA9	31.25 pg/mL-2000 pg/mL	7.81 pg/mL
Human T-cell surface glycoprotein CD3 zeta chain (CD247) ELISA kit	CSB-EL004904HU	CD247	0.156 ng/mL-10 ng/mL	0.039 ng/mL
Human Programmed Death Ligand-1(PD-L1/CD274) ELISA Kit	CSB-E13644h	CD274	15.6 pg/mL-1000 pg/mL	3.9 pg/mL
Mouse Programmed cell death 1 ligand 1(CD274) ELISA kit	CSB-EL004911MO	CD274	31.25 pg/mL-2000 pg/mL	7.81 pg/mL
Human Soluble CD276,sCD276/sB7-H3 ELISA Kit	CSB-E14285h	CD276	3.12 ng/mL-200 ng/mL	0.78 ng/mL
Human soluble cluster of differentiation 28,sCD28 ELISA Kit	CSB-E09296h	CD28	0.625 ng/mL-40 ng/mL	0.156 ng/mL
Mouse Tumor necrosis factor receptor superfamily member 5(CD40) ELISA kit	CSB-EL004936MO	CD40	Request Information	Request Information
Human cluster Of differentiation,CD44 ELISA Kit	CSB-E11846h	CD44	78 pg/mL-5000 pg/mL	19.5 pg/mL
Human Leukocyte surface antigen CD47(CD47) ELISA kit	CSB-EL004940HU	CD47	3.12 pg/mL-200 pg/mL	0.78 pg/mL
Mouse Leukocyte surface antigen CD47(CD47) ELISA kit	CSB-EL004940MO	CD47	15.6 pg/mL-1000 pg/mL	3.9 pg/mL
Human carcinoembryonic antigen,CEA ELISA Kit	CSB-E04767h	CEACAM5	5 ng/mL-120 ng/mL	2 ng/mL
Mouse carcinoembryonic antign,CEA ELISA Kit	CSB-E13925m	CEACAM5	62.5 pg/mL-4000 pg/mL	15.6 pg/mL
Human Macrophage Colony-Stimulating Factor Receptor,M-CSFR ELISA Kit	CSB-E10012h	CSF1R	0.156 ng/mL-10 ng/mL	0.039 ng/mL
Rat Macrophage colony-stimulating factor 1 receptor(CSF1R) ELISA kit	CSB-EL006044RA	CSF1R	0.312 ng/mL-20 ng/mL	0.078 ng/mL
Human Granulocyte-Macrophage Colony Stimulating Factor,GM-CSF ELISA Kit	CSB-E04568h	CSF2	15.6 pg/mL-1000 pg/mL	3.9 pg/mL
Mouse Granulocyte-Macrophage Colony Stimulating Factor,GM-CSF ELISA Kit	CSB-E04569m	CSF2	15.6 pg/mL-1000 pg/mL	3.9 pg/mL
Rat Granulocyte-Macrophage Colony Stimulating Factor,GM-CSF ELISA Kit	CSB-E04570r	CSF2	15.6 pg/ml - 1000 pg/ml	3.9 pg/ml
Human cytotoxic T lymphocyte associated antigen 4,CTLA-4 ELISA Kit	CSB-E09171h	CTLA4	125 pg/mL-8000 pg/mL	31.25 pg/mL
Mouse cytotoxic T lymphocyte associated antigen 4,CTLA-4 ELISA Kit	CSB-E13637m	CTLA4	0.312 ng/mL-20 ng/mL	0.078 ng/mL
Human epidermal growth factor receptor,EGFR ELISA Kit	CSB-E12124h	EGFR	0.312 ng/mL-20 ng/mL	0.019 ng/mL

• 1
• 2
• 3
• 4
• 5
• 6

Click to view CUSABIO Cytokine ELISA kits

Drug Development Solutions

ADC Development Solutions

mRNA Vaccine Research Solutions

CAR-T Therapy Development Solutions

Webinars

Exploring Antibody-Drug Conjugates (ADCs) Pharmacokinetics (PK) /Pharmacodynamics (PD) Profiles with Anti-payload Antibodies

Targeting Transmembrane Proteins: Facilitating Rapid Advancement in Therapeutic Antibody Discovery

Antibody-Drug Conjugates (ADCs): Current Research and Overcoming Challenges

Recombinant Protein DT3C: A Convenient Tool for Antibody Internalization Analysis